BCMA(CD269) decoy receptor shows potential to treat Multiple Myeloma and Large B cell Lymphoma

By /

Using a yeast display system, his group developed a BCMA mutant with higher affinity to TNF ligands APRIL and BAFF. This soluble decoy receptor showed anti-tumor effects in vitro and in vivo using mouse MM1.R and INA-6 tumor models.

“Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma” Yu Rebecca Miao, Amato J Giaccia, et al. J Exp Med 2022 Sep 5;219(9):e20220214. doi: 10.1084/jem.20220214. Epub 2022 Jul 26. PMID: 35881112

Relevant Ancell Products:

Recombinant human BCMA(CD269)-muIg

Recombinant human BAFFR(CD268)-muIg

Recombinant human BAFF(CD257)-muCD8

anti-human CD38 mAb